<SEC-DOCUMENT>0001104659-21-010186.txt : 20210201
<SEC-HEADER>0001104659-21-010186.hdr.sgml : 20210201
<ACCEPTANCE-DATETIME>20210201161907
ACCESSION NUMBER:		0001104659-21-010186
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210201
DATE AS OF CHANGE:		20210201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroBo Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001638287
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472389984
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-252412
		FILM NUMBER:		21576922

	BUSINESS ADDRESS:	
		STREET 1:		200 BERKELEY ST.
		STREET 2:		FL 19
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		(857) 702-9600

	MAIL ADDRESS:	
		STREET 1:		200 BERKELEY ST.
		STREET 2:		FL 19
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Gemphire Therapeutics Inc.
		DATE OF NAME CHANGE:	20150331
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>tm213982d4_424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Filed Pursuant to Rule 424(b)(3)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Registration No. 333-252412</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>EXPLANATORY NOTE:</B> The purpose of this
filing is to correct a typographical error in the Rule 424(b)(3) filing of NeuroBo Pharmaceuticals, Inc. filed with the Securities
and Exchange commission on January 29, 2021.&nbsp; The number of shares of Common Stock owned and maximum number of shares of
Common Stock to be sold for one of the Selling Stockholders contained a typographical error in the original prospectus.&nbsp;
This filing corrects such typographical error.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm213982d3_424b3img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5,000,000 Shares of Common Stock<BR>
Offered by the Selling Stockholders</B></P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This prospectus
relates to the resale from time to time of up to 5,000,000 shares of common stock of NeuroBo Pharmaceuticals, Inc. by the
Selling Stockholders listed on page 10 (the &ldquo;Selling Stockholders&rdquo;), including their pledgees, assignees, donees,
transferees or their respective successors-in-interest, which consist of 2,500,000 outstanding shares of our common stock
held by the Selling Stockholders and 2,500,000 shares of our common stock issuable upon the exercise of outstanding warrants
held by the Selling Stockholders to purchase shares of our common stock (the &ldquo;Warrants&rdquo;). We will not receive any
proceeds from the sale of the shares offered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have agreed, pursuant
to a registration rights agreement that we have entered into with the Selling Stockholders, to bear all of the expenses incurred
in connection with the registration of these shares. The Selling Stockholders will pay or assume discounts, commissions, fees
of underwriters, selling brokers or dealer managers and similar expenses, if any, incurred for the sale of these shares of our
common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Selling Stockholders
identified in this prospectus, or their pledgees, assignees, donees, transferees or their respective successors-in-interest, may
offer the shares from time to time on terms to be determined at the time of sale through ordinary brokerage transactions or through
any other means described in this prospectus under the caption &ldquo;Plan of Distribution.&rdquo; The shares may be sold at fixed
prices, at prevailing market prices, at prices related to prevailing market prices or at negotiated prices. For a list of the
Selling Stockholders, see the section entitled &ldquo;Selling Stockholders&rdquo; on page 10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We may amend or supplement
this prospectus from time to time by filing amendments or supplements as required. You should read the entire prospectus and any
amendments or supplements carefully before you make your investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our common stock is
traded on The Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;NRBO.&rdquo; On January 22, 2021, the last
reported closing sale price of our common stock on Nasdaq was $5.13 per share. You are urged to obtain current market quotations
for our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We are an &ldquo;emerging
growth company&rdquo; under applicable Securities and Exchange Commission rules and, as such, have elected to comply with certain
reduced public company disclosure requirements for this prospectus and future filings. See &ldquo;Prospectus Summary&mdash;Implications
of Being an Emerging Growth Company.&rdquo;</P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Investing in our common stock
involves a high degree of risk. See &ldquo;<A HREF="#a_001"><FONT STYLE="color: #0000EE">Risk Factors</FONT></A>&rdquo;
beginning on page 4   of this prospectus and in the documents incorporated by reference into this prospectus. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or
accuracy of this prospectus. Any representation to the contrary is a criminal offense. &nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is
January 29, 2021.</B></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left"><A HREF="#az_001">PROSPECTUS
    SUMMARY</A></TD>
    <TD STYLE="width: 10%; text-align: right"><A HREF="#az_001">1</A></TD></TR>
<TR STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#az_002">THE OFFERING</A></TD>
    <TD STYLE="text-align: right"><A HREF="#az_002">4</A></TD></TR>
<TR STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_001">RISK FACTORS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_001">4</A></TD></TR>
<TR STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#az_003">CAUTIONARY
    NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#az_003">7</A></TD></TR>
<TR STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#az_004">USE OF PROCEEDS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#az_004">9</A></TD></TR>
<TR STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#az_005">PRIVATE PLACEMENT
    OF SHARES OF COMMON STOCK AND WARRANTS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#az_005">9</A></TD></TR>
<TR STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#az_006">SELLING STOCKHOLDERS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#az_006">10</A></TD></TR>
<TR STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#az_007">PLAN OF DISTRIBUTION</A></TD>
    <TD STYLE="text-align: right"><A HREF="#az_007">13</A></TD></TR>
<TR STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#az_008">LEGAL MATTERS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#az_008">14</A></TD></TR>
<TR STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#az_009">EXPERTS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#az_009">14</A></TD></TR>
<TR STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#az_010">WHERE YOU CAN
    FIND MORE INFORMATION</A></TD>
    <TD STYLE="text-align: right"><A HREF="#az_010">14</A></TD></TR>
<TR STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#az_011">INCORPORATION
    OF CERTAIN DOCUMENTS BY REFERENCE</A></TD>
    <TD STYLE="text-align: right"><A HREF="#az_011">14</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This prospectus is
part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, utilizing a &ldquo;shelf&rdquo;
registration process. Under this shelf registration process, the Selling Stockholders may, from time to time, sell the shares
of common stock described in this prospectus in one or more offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Neither we, nor the
Selling Stockholders, have authorized anyone to give any information or to make any representation other than those contained
or incorporated by reference in this prospectus. You must not rely upon any information or representation not contained or incorporated
by reference in this prospectus. The Selling Stockholders are offering to sell, and seeking offers to buy, shares of our common
stock only in jurisdictions where it is lawful to do so. This prospectus does not constitute an offer to sell or the solicitation
of an offer to buy any shares other than the registered shares to which they relate, nor does this prospectus constitute an offer
to sell or the solicitation of an offer to buy shares in any jurisdiction to any person to whom it is unlawful to make such offer
or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus is accurate on any
date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is
correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus is delivered
or shares are sold on a later date. Our business, financial condition, results of operations and prospects may have changed since
those dates. This prospectus incorporates by reference market data and industry statistics and forecasts that are based on independent
industry publications and other publicly available information. Although we believe these sources are reliable, we do not guarantee
the accuracy or completeness of this information and we have not independently verified this information. In addition, the market
and industry data and forecasts that may be included or incorporated by reference in this prospectus may involve estimates, assumptions
and other risks and uncertainties and are subject to change based on various factors, including those discussed under the heading
 &ldquo;Risk Factors&rdquo; contained in this prospectus, and under similar headings in other documents that are incorporated by
reference into this prospectus. Accordingly, investors should not place undue reliance on this information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1pt solid; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B><A NAME="az_001"></A>PROSPECTUS
SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>This summary highlights certain information
appearing elsewhere in this prospectus and the documents incorporated by reference. This summary does not contain all of the information
you should consider before investing in our common shares. You should read this entire prospectus and the documents incorporated
by reference into this prospectus carefully before making an investment decision. References in this prospectus to &ldquo;we,&rdquo;
 &ldquo;us,&rdquo; &ldquo;our&rdquo; and &ldquo;Company&rdquo; refer to NeuroBo Pharmaceuticals,&nbsp;Inc. and its consolidated
subsidiaries.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Business Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">NeuroBo Pharmaceuticals,&nbsp;Inc.
(together with its subsidiaries, the &ldquo;Company&rdquo; or &ldquo;NeuroBo&rdquo;), formerly known as Gemphire Therapeutics
Inc., is a clinical-stage biotechnology company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">NeuroBo has a number
of therapeutics programs and product candidates designed to impact a range of indications including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><I>ANA-001,
                                         </I><FONT STYLE="font-family: Times New Roman, Times, Serif">our lead drug candidate,
                                         is a proprietary oral niclosamide formulation and was developed as a treatment for patients
                                         with moderate COVID-19. Niclosamide is a potential oral antiviral and anti-inflammatory
                                         agent with a long history of use and well-understood safety in humans. ANA-001 is currently
                                         being studied in a 60-subject Phase&nbsp;2 clinical trial conducted in the United States.
                                         We plan to conduct the Phase 2 trial and to initiate its Phase&nbsp;3 development program
                                         for ANA-001 in the third quarter of 2021;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><I>NB-01</I>,
                                         which is primarily focused on the development of a treatment for painful diabetic neuropathy,
                                         but which the Company believes could also treat a range of neuropathic conditions, including
                                         chemotherapy-induced peripheral neuropathy and post-traumatic peripheral neuropathy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><I>NB-02</I>,
                                         which has the potential to treat the symptoms of cognitive impairment and modify the
                                         progression of neurodegenerative diseases associated with the malfunction of a protein
                                         called tau, and with amyloid beta plaque deposition; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><I>Gemcabene</I>,
                                         which is focused&nbsp;<FONT STYLE="background-color: white">on developing and commercializing
                                         therapies for the treatment of dyslipidemia, a serious medical condition that increases
                                         the risk of life-threatening cardiovascular disease, focused on orphan indications such
                                         as homozygous familial hypercholesterolemia, as well as nonalcoholic fatty liver disease/nonalcoholic
                                         steatohepatitis.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Current Scientific Activity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In light of the present
business environment, including the impact of the COVID-19 pandemic, the Company is currently conducting the scientific activities
described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B><I>ANA-001. </I></B>ANA-001
is currently being tested in a Phase 2/3 clinical trial. We believe that expanding our product pipeline into the infectious disease
space will further the development of COVID-19 related treatments that are desperately needed. ANA-001 is a proprietary oral niclosamide
formulation and was developed as a treatment for patients with moderate COVID-19. Niclosamide is a potential oral antiviral and
anti-inflammatory agent with a long history of use and well-understood safety in humans. ANA-001 is currently being studied in
a 60-subject Phase&nbsp;2 clinical trial conducted in the United States. We plan to finalize the Phase 2 trial and to initiate
the Phase&nbsp;3 development program for ANA-001 in the third quarter of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B><I>NB-01.&nbsp;</I></B>For
NB-01, the Company has determined that any attempt to conduct Phase 3 clinical trials, as previously announced, would be difficult
if not impossible in the short or medium term. Accordingly, in the first quarter of 2020, the Company directed its contract research
organization partners and other vendors working on the Phase 3 clinical trials of NB-01 to cease all work and the Company terminated
its existing contract arrangements with each of them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company is currently evaluating its
options regarding the NB-01 asset:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1pt solid; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><I>Orphan drug</I>.
                                         Development of NB-01 as an orphan drug is among the alternatives the Company is considering.
                                         The Company has identified one potential rare disease indication for NB-01, but the Company
                                         has not yet conducted feasibility studies for it. The Company believes that development
                                         for such indication would depend on its ability to renegotiate milestone payments under
                                         its exclusive license agreement with Dong-A ST to reflect the potential revenue from
                                         such indication.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><I>Nutraceutical</I>.
                                         The Company has considered marketing NB-01 as a nutraceutical (non-pharmaceutical) product,
                                         and the Company may re-explore this pathway if the identified rare disease indication
                                         for NB-01 does not proceed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B><I>NB-02</I></B><I>.&nbsp;</I>During
the third quarter of 2020, the Company continued work on preparing an Investigational New Drug (&ldquo;IND&rdquo;) application
to the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) for NB-02. In order to preserve operating capital, the Company has
postponed continued work on the IND and the first human clinical trials for NB-02 until global health and macroeconomic conditions
improve, with a view toward commencing clinical trial activity in the second half of 2021, subject to improvement of the constraints
imposed by the COVID-19 pandemic. The Company is also considering engaging with a strategic partner to assist with clinical trials
for NB-02.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B><I>Gemcabene</I></B>.
In May 2020, the Company received written communication from the FDA that the clinical development program for Gemcabene remains
on a partial clinical hold. The Company continues to review its options regarding Gemcabene.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On December 31, 2020,
NeuroBo acquired ANA Therapeutics, Inc. (&ldquo;ANA&rdquo;), a privately held biotechnology company developing ANA-001, a proprietary
capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19.
The transaction was unanimously approved by each of the board of directors of the Company and ANA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">ANA-001 is a proprietary
oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19 (patients not requiring
ventilators). Niclosamide is a potential oral antiviral and anti-inflammatory agent with a long history of use and a well-understood
safety profile in humans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">ANA-001 is currently
being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the U.S. Niclosamide has demonstrated
both antiviral and immunomodulatory activity with possible downstream effects on coagulation abnormalities observed in COVID-19.
In preclinical research by an independent academic group published in Antimicrobial Agents and Chemotherapy, niclosamide inhibited
viral replication in vitro and was more potent than remdesivir in the same assay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Specifically, studies
have shown that niclosamide prevents replication of SARS-CoV-2 at very low concentrations and that the compound appears to exhibit
three distinct mechanisms of action:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">acting
                                         as a potent antiviral to a broad homology of other viruses including influenza;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">reducing
                                         inflammation without suppressing the immune system; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">providing
                                         bronchodilation, which is a useful pulmonary mechanism for at-risk patients with underlying
                                         cardiovascular and/or pulmonary conditions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As a result, we believe
ANA-001 has the potential to reduce the viral load and inflammation associated with cytokine dysregulation, acute respiratory
distress syndrome (ARDS), and coagulation abnormalities and thus improve time to clinical improvement as defined as hospital discharge
recorded using the WHO Ordinal Scale for Clinical Improvement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe ANA-001 has distinct competitive
advantages in this market, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">offering an
                                         effective treatment for moderate to severe COVID-19 (patients not requiring ventilators);</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>having 3+ year marketing exclusivity in the U.S. upon FDA
                                         approval;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

</DIV>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1pt solid; padding-right: 5pt; padding-left: 5pt"><P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">providing ease
                                         of administration via a capsule formulation and potential to dramatically lower overall
                                         treatment cost; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">possessing a proven safety profile (generic niclosamide
                                         has been used safely for 50 years as a treatment for tapeworm infections).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">In October 2020, a Phase 2/3
clinical trial evaluating ANA-001 as a treatment for COVID-19 was initiated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The two-part Phase
2/3 multi-center, double blind, placebo-controlled study to assess the safety, tolerability, and efficacy of ANA-001 is being
conducted at up to 20 clinical sites in the U.S. In both phases of the study, hospitalized patients with moderate to severe COVID-19
(patients not requiring ventilators) will be administered a seven-day course of ANA-001 (niclosamide capsules) in addition to
standard-of-care treatment. The first phase of the trial will enroll 60 patients. The primary objective of the first phase of
the trial is to assess safety and tolerability; secondary objectives include measurements of efficacy (median time to hospital
discharge) and pharmacokinetics. The Company expects to complete enrollment of the first phase of the study and to have topline
data from this segment of the trial in the third quarter of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The second phase of
the trial is expected to enroll several hundred patients, with the primary endpoints of the study being median time to hospital
discharge, safety and tolerability. Secondary objectives will evaluate clinical improvement and the need and duration for rescue
therapy.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-align: left; text-indent: 0.5in">Our principal
executive offices are located at 200 Berkeley Street, 19<SUP>th</SUP> Floor, Boston, Massachusetts, 02116, and our telephone number is (857) 702-9600. Our website address
is <U>www.neurobopharma.com.</U> The information contained on, or that can be accessed through, our website is not a part of this
prospectus. We make available free of charge on www.neurobopharma.com our annual, quarterly and current reports, and amendments
to those reports, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.
The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers
that file electronically with the SEC at <U>http://www.sec.gov.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-align: left; text-indent: 0.5in">Our common
stock trades on the Nasdaq Capital Market under the symbol &ldquo;NRBO&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Implications of Being an Emerging Growth Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We are an &ldquo;emerging
growth company&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;). As a result,
we may take advantage of reduced reporting requirements that are otherwise applicable to public companies, including delaying
auditor attestation of internal control over financial reporting and reducing executive compensation disclosures. The JOBS Act
also provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised
accounting standards. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject
to the same new or revised accounting standards as other public companies that are not emerging growth companies. Because we intend
to rely on certain disclosure and other requirements of the JOBS Act, the information contained herein may be different than the
information you receive from other public companies in which you hold stock. In addition, it is possible that some investors will
find our common stock less attractive as a result of our determination to avail ourselves of exemptions under the JOBS Act, which
may result in a less active trading market for our common stock and higher volatility in our stock price. We will remain an emerging
growth company until the earlier to occur of: (1)&nbsp;the last day of the fiscal year in which we have total annual gross revenues
of $1.07&nbsp;billion or more; (2)&nbsp;the last day of the fiscal year following the fifth anniversary of the date of the closing
of our initial public offering; (3)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during
the previous three years; or (4)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the Securities
and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="az_002"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 25%; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common
                                         stock offered by Selling Stockholders:</B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 73%; text-align: left"><P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">5,000,000 shares, consisting of 2,500,000 outstanding shares of our common stock,
                                                                                                            2,500,000 shares of our common stock issuable upon the exercise of Warrants.</P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; font-size: 10pt; font-weight: bold; vertical-align: top">Use of proceeds:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">We will not receive any proceeds
    from the sale of shares in this offering.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; font-size: 10pt; font-weight: bold; vertical-align: top">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; font-weight: bold; text-align: left">Risk factors:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">You should read the &ldquo;Risk
    Factors&rdquo; section on page 4 of this prospectus for a discussion of factors to consider carefully before deciding to invest
    in shares of our common stock.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nasdaq
                                         Capital Market symbol:</B></P></TD><TD STYLE="text-align: left; font-size: 10pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt; vertical-align: top">&ldquo;NRBO&rdquo;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_001"></A><B>RISK
FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Investing in our common
stock involves a high degree of risk. Before you decide to invest in our common stock, you should carefully consider the risks
described in the section captioned &ldquo;Risk Factors&rdquo; in our most recent <A HREF="http://www.sec.gov/Archives/edgar/data/1638287/000155837020003385/nrbo-20191231x10k.htm" STYLE="-sec-extract: exhibit">Annual Report on Form 10-K</A>, our most recent <A HREF="http://www.sec.gov/Archives/edgar/data/1638287/000155837020013826/nrbo-20200930x10q.htm" STYLE="-sec-extract: exhibit">Quarterly Report on Form 10-Q</A> and other filings we make with the Securities and Exchange Commission (&ldquo;SEC&rdquo;), from time to
time, which are incorporated by reference herein in their entirety, together with the other information in this prospectus and
documents incorporated by reference in this prospectus. The risks described in our most recent <A HREF="http://www.sec.gov/Archives/edgar/data/1638287/000155837020003385/nrbo-20191231x10k.htm" STYLE="-sec-extract: exhibit">Annual Report on Form 10-K</A>, our most recent <A HREF="http://www.sec.gov/Archives/edgar/data/1638287/000155837020013826/nrbo-20200930x10q.htm" STYLE="-sec-extract: exhibit">Quarterly Report on Form 10-Q</A> and the other filings incorporated by reference herein are not the only ones facing our company. Additional
risks and uncertainties may also impair our business operations. If any of the risks described in our most recent <A HREF="http://www.sec.gov/Archives/edgar/data/1638287/000155837020003385/nrbo-20191231x10k.htm" STYLE="-sec-extract: exhibit">Annual Report on Form 10-K</A>, our most recent <A HREF="http://www.sec.gov/Archives/edgar/data/1638287/000155837020013826/nrbo-20200930x10q.htm" STYLE="-sec-extract: exhibit">Quarterly Report on Form 10-Q</A> and the other filings incorporated by reference herein occurs, our business, financial condition, results
of operations and future growth prospects could be harmed. In these circumstances, the market price of our common stock could
decline, and you may lose all or part of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Risks Related to the Acquisition
of ANA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not obtain all of the benefits
or recognize all of the synergies we anticipate from the ANA acquisition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We acquired ANA because
we believe that the combination of our companies will result in a stronger competitive company. However, we may encounter unanticipated
events which could keep us from recognizing the benefits we anticipate from the acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The results of the
combined company following the acquisition will depend in part upon the Company&rsquo;s ability to integrate ANA&rsquo;s business
with the Company&rsquo;s business in an efficient and effective manner. The Company&rsquo;s attempt to integrate two companies
that have previously operated independently may result in significant challenges, and the Company may be unable to accomplish
the integration smoothly or successfully. The integration may require the dedication of significant management resources, which
may temporarily distract management&rsquo;s attention from the day-to-day operations of the businesses of the combined company.
In addition, the combined company may adjust the way in which ANA or the Company has conducted its operations and utilized its
assets, which may require retraining and development of new procedures and methodologies. The process of integrating operations
and making such adjustments after the acquisition could cause an interruption of, or loss of momentum in, the activities of one
or more of the combined company&rsquo;s businesses and the loss of key personnel. Employee uncertainty, lack of focus, or turnover
during the integration process may also disrupt the businesses of the combined company. Any inability of management to integrate
the operations of the Company and ANA successfully could have a material adverse effect on the business and financial condition
of the combined company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, the acquisition
subjects the Company to contractual and other obligations and liabilities of ANA, some of which may be unknown. Although the Company
and its legal and financial advisors have conducted due diligence on ANA and its business, there can be no assurance that the
Company is aware of all obligations and liabilities of ANA. These liabilities, and any additional risks and uncertainties related
to ANA&rsquo;s business and to the acquisition not currently known to the Company or that the Company may currently be aware of,
but that prove to be more significant than assessed or estimated by the Company, could negatively impact the business, financial
condition, and results of operations of the combined company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>The work required to integrate ANA
and the Company may divert management resources from operational matters and other strategic opportunities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We expect that the
successful integration of ANA&rsquo;s operations and their personnel will require substantial management time and attention. The
amount of time that our management will be required to devote to the integration may divert their attention from the day-to-day
operation of the business or other strategic opportunities. In addition, uncertainty regarding the acquisition, the integration
process, and its impact on our customers, partners, employees and regulatory compliance may create additional demands on management&rsquo;s
time and resources. If diversion of our management&rsquo;s attention impairs our results of operations or our ability to identify
and pursue strategic opportunities, our share price could be negatively impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to ANA-001</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B><I>Our pursuit
of potential therapeutic and prophylactic treatments for&nbsp;COVID-19&nbsp;is at an early stage and subject to many risks. We
may be unable to receive approval for any of our&nbsp;COVID-19&nbsp;product candidates a timely manner, if at all, and our&nbsp;COVID-19&nbsp;product
candidate may never be approved.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We may experience
difficulties or delays in enrolling patients in clinical trials due to the impact of the global&nbsp;COVID-19&nbsp;pandemic or
other reasons. Many of the risks related to the development of these product candidates are beyond our control, including risks
related to clinical development, the regulatory submission process, potential threats to our intellectual property rights and
manufacturing delays or difficulties. We may be unable to produce an efficacious and/or approved product for the treatment of
patients with early&nbsp;COVID-19&nbsp;in a timely manner, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The results of preclinical
studies from our&nbsp;COVID-19&nbsp;product candidates may not be predictive of the results of clinical trials, and the results
of any early-stage clinical trials we commence may not be predictive of the results of the later-stage clinical trials. There
can be no assurance that any of our clinical trials for our&nbsp;COVID-19&nbsp;product candidates, or any other of our product
candidates, will ultimately be successful or support further clinical development. In addition, the interpretation of the data
from our clinical trials of&nbsp;ANA-001 by FDA and other regulatory agencies may differ from our interpretation of such data
and the FDA or other regulatory agencies may require that we conduct additional studies or analyses. Any of these factors could
delay or prevent us from receiving regulatory approval of&nbsp;ANA-001 and there can be no assurance that our product candidate
will be approved in a timely manner, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If the&nbsp;COVID-19&nbsp;outbreak
is effectively contained or the risk of coronavirus infection is diminished or eliminated before we can successfully develop and
manufacture our product candidate, the commercial viability of such product candidate may be diminished or eliminated. We are
also committing financial resources and personnel to the development of this product candidate which may cause delays in or otherwise
negatively impact our other development programs, despite uncertainties surrounding the longevity and extent of coronavirus as
a global health concern. Our business could be negatively impacted by our allocation of significant resources to a global health
threat that is unpredictable and could rapidly dissipate or against which our treatment, if successfully developed, may not be
effective. In addition, other parties are currently producing therapeutic and vaccine candidates for&nbsp;COVID-19,&nbsp;which
may be more efficacious or may be approved prior to&nbsp;our product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>The regulatory pathway for&nbsp;ANA-001
is continually evolving, and may result in unexpected or unforeseen challenges.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The speed at which
parties are acting to create and test many therapeutics and vaccines for&nbsp;COVID-19&nbsp;is unusual, and evolving or changing
plans or priorities within the FDA, including those based on new knowledge of&nbsp;COVID-19&nbsp;and how the disease affects the
human body, may significantly affect the regulatory timeline for our product candidates. Results from ongoing clinical trials
and discussions with regulatory authorities may raise new questions and require us to redesign proposed clinical trials, including
revising proposed endpoints or adding new clinical trial sites or cohorts of subjects. Any such developments could delay the development
timeline for our product candidates and materially increase the cost of the development for such candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>In light of the COVID-19 pandemic,
it is possible that one or more government entities may take actions that directly or indirectly have the effect of abrogating
some of our rights or opportunities. If we were to develop a treatment for COVID-19, the economic value of such a therapeutic
treatment to us could be limited.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Various government
entities, including the U.S. government, are offering incentives, grants and contracts to encourage additional investment by commercial
organizations into preventative and therapeutic agents against coronavirus, which may have the effect of increasing the number
of competitors and/or providing advantages to known competitors. Accordingly, there can be no assurance that we will be able to
successfully establish a competitive market share for our COVID-19 therapeutic treatment, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Even if we obtain favorable clinical
results, we may not be able to obtain regulatory approval for, or successfully commercialize ANA-001.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We are not permitted
to market ANA-001 in the United States until we receive approval of an NDA from the FDA, or in any foreign countries until we
receive the requisite approval from such countries. As a condition to submitting an NDA to the FDA for ANA-001, we must complete
our ongoing Phase 2 clinical trial, conduct and complete further Phase 3 clinical trials, and any additional nonclinical studies
or clinical trials required by the FDA. To date, we have only completed the Phase 1 Single Ascending Dosing (SAD) study. ANA-001
may not be successful in clinical trials or receive regulatory approval. Further, ANA-001 may not receive regulatory approval
even if it is successful in clinical trials. Obtaining approval of an NDA is a complex, lengthy, expensive and uncertain process
that typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the
substantial discretion of the regulatory authorities. In addition, the policies or regulations, or the type and amount of clinical
data necessary to gain approval, may change during the course of a product candidate&rsquo;s clinical development and may vary
among jurisdictions. Our development activities could be harmed or delayed by a partial shutdown of the U.S. government, including
the FDA. We have not obtained regulatory approval for any product candidate and it is possible that ANA-001 will never obtain
regulatory approval. The FDA may delay, limit or deny approval of ANA-001 for many reasons, including, among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the results
                                         of our clinical trials may not meet the level of statistical or clinical significance
                                         required by the FDA for marketing approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the FDA may
                                         disagree with the number, design, size, conduct or implementation of our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the FDA may
                                         not approve the formulation, labeling or specifications of ANA-001;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the FDA may
                                         require that we conduct additional clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the contract
                                         research organizations (&ldquo;CROs&rdquo;) or the clinical investigators that we retain
                                         to conduct our clinical trials may take actions outside of our control that materially
                                         adversely impact our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">we, our CROs
                                         or clinical investigators may fail to perform in accordance with the FDA&rsquo;s good
                                         clinical practice (&ldquo;GCP&rdquo;) requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the FDA may
                                         disagree with our interpretation of data from our preclinical studies and clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the FDA may
                                         find deficiencies with the manufacturing processes or facilities of third-party manufacturers
                                         with which we contract; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the
                                         policies or regulations of the FDA may significantly change in a manner that renders
                                         our clinical data insufficient for approval or may require that we amend or submit new
                                         clinical protocols.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, similar
reasons may cause the EMA or other regulatory authorities to delay, limit or deny approval of ANA-001 outside the United States.
Any of these factors, many of which are beyond our control, could jeopardize our ability to obtain regulatory approval for and
successfully market ANA-001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Alternatively, even
if we obtain regulatory approval, that approval may be for indications or patient populations that are not as broad as we intend
or desire or may require labeling that includes significant use or distribution restrictions or safety warnings. We may also be
required to perform additional, unanticipated clinical trials to obtain approval or be subject to additional post marketing testing
requirements to maintain regulatory approval. In addition, regulatory authorities may withdraw their approval of a product or
the FDA may require a risk evaluation and mitigation strategy (&ldquo;REMS&rdquo;) for a product, which could impose restrictions
on its distribution. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We face substantial competition,
which may result in others discovering, developing or commercializing products before, or more successfully, than we do.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The development and
commercialization of new products is highly competitive. Our future success depends on our ability to demonstrate and maintain
a competitive advantage with respect to the development and commercialization of our product candidates. Our objective is to develop
and commercialize new products with superior efficacy, convenience, tolerability and safety. In many cases, the products that
we commercialize will compete with existing, market-leading products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Many of our potential
competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than
we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals,
recruiting patients and in manufacturing pharmaceutical products. In particular, these companies have greater experience and expertise
in securing government contracts and grants to support their research and development efforts, conducting testing and clinical
trials, obtaining regulatory approvals to market products, manufacturing such products on a broad scale and marketing approved
products. These companies also have significantly greater research and marketing capabilities than we do and may also have products
that have been approved or are in late stages of development, and have collaborative arrangements in our target markets with leading
companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and
development of novel compounds or to in-license novel compounds that could make the product that we develop obsolete. As a result
of all of these factors, our competitors may succeed in obtaining patent protection and/or FDA approval or discovering, developing
and commercializing products before, or more effectively than, we do. In addition, any new product that competes with an approved
product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition
and to be commercially successful. If we are not able to compete effectively against potential competitors, our business will
not grow and our financial condition and operations will suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="az_003"></A><B>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This prospectus and
the documents incorporated by reference herein contain forward-looking statements that involve substantial risks and uncertainties.
All statements, other than statements of historical facts, contained in this prospectus or incorporated by reference herein, including
statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans
and objectives of management and expected market growth, are forward-looking statements. We may, in some cases, use words such
as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo;
 &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;target,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo;
 &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; or the negative of those terms, and similar
expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. In addition, statements
that &ldquo;we believe&rdquo; and similar statements reflect our beliefs and opinions on the relevant subject. The forward-looking
statements and opinions contained in this prospectus and incorporated by reference herein are based upon information available
to us as of the date such statements are made and, while we believe such information forms a reasonable basis for such statements
at the time made, such information may be limited or incomplete, and our statements should not be read to indicate that we have
conducted an exhaustive inquiry into, or review of, all potentially available relevant information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These forward-looking
statements include, among other things, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">our
                                         plans to initiate and expand clinical trials of our product candidates and our expectations
                                         for the timing, quantity and quality of information to be reported from our clinical
                                         trials of ANA-001, NB-01, NB-02 and Gemcabene;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">planned
                                         clinical trials for our product candidates, whether conducted by us or by any future
                                         collaborators, including the timing of these trials and of the anticipated results;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">our
                                         ability to discover and develop compounds suitable for clinical development and the timing
                                         for designation of future development candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">our
                                         ability to replicate in any clinical trial of one of our product candidates the results
                                         we observed in preclinical or earlier clinical studies of such product candidate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         plans to research, develop, seek approval for, manufacture and commercialize our current
                                         and future product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">our
                                         plans to develop and seek approval of companion diagnostic tests for use in identifying
                                         patients who may benefit from treatment with our products and product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">our
                                         ability to enter into, and the terms and timing of, any collaborations, license agreements,
                                         or other arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         potential benefits of any future collaboration;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">developments
                                         relating to our competitors and our industry;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         impact of government laws and regulations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the
                                         timing of and our ability to file new drug applications and obtain and maintain regulatory
                                         approvals for our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the
                                         rate and degree of market acceptance and clinical utility of any products for which we
                                         receive marketing approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">our
                                         commercialization, marketing and manufacturing capabilities and strategy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         intellectual property position and strategy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">our
                                         ability to identify additional products or product candidates with significant commercial
                                         potential;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">our
                                         expectations related to the use of our current cash and cash equivalents and the period
                                         of time in which such capital will be sufficient to fund our planned operations; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">our
                                         estimates regarding expenses, future revenue, capital requirements and need for additional
                                         financing; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">other
                                         risks and uncertainties, including those listed under the caption &ldquo;Risk Factors&rdquo;
                                         in our most recent <A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000155837020003385/nrbo-20191231x10k.htm" STYLE="-sec-extract: exhibit">Annual Report on Form 10-K</A>, our most recent <A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000155837020013826/nrbo-20200930x10q.htm" STYLE="-sec-extract: exhibit">Quarterly Report on Form 10-Q</A>, and other filings
                                         we make with the SEC.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We may not actually
achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations
disclosed in the forward-looking statements we make. New risks and uncertainties emerge from time to time, and it is not possible
for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained or incorporated
by reference in this prospectus. We have included important factors in the cautionary statements included or incorporated by reference
in this prospectus, particularly in the &ldquo;Risk Factors&rdquo; section, that could cause actual results or events to differ
materially from the forward-looking statements that we make. In particular, the extent to which the COVID-19 outbreak continues
to impact our operations and those of the third parties on which we rely will depend on future developments, which are highly
uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, additional or modified
government actions, and the actions that may be required to contain the virus or treat its impact. COVID-19 has and may continue
to adversely impact our operations and workforce, including our discovery research, supply chain and clinical trial operations
activities, which in turn could have an adverse impact on our business and financial results. Our forward-looking statements also
do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments
that we may make or enter into.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">You should read this
prospectus, the documents incorporated by reference in this prospectus and the documents that we have filed as exhibits to the
registration statement of which this prospectus is a part completely and with the understanding that our actual future results
may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether
as a result of new information, future events or otherwise, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B><A NAME="az_004"></A>USE
OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We are filing the
registration statement of which this prospectus forms a part to permit the holders of the shares of our common stock described
in the section entitled &ldquo;Selling Stockholders&rdquo; to resell such shares. We are not selling any securities under this
prospectus and we will not receive any proceeds from the sale or other disposition of shares of our common stock held by the Selling
Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Selling Stockholders
will pay any placement agent discounts and commissions and expenses incurred by the Selling Stockholders for brokerage, accounting,
tax or legal services or any other expenses incurred by the Selling Stockholders in disposing of these shares. We will bear all
other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus, including, without
limitation, all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our accountants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="az_005"></A><B>PRIVATE PLACEMENT
OF SHARES OF COMMON STOCK AND WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On January 18, 2021,
we entered into a Securities Purchase Agreement with each of the Selling Stockholders named herein, see &ldquo;Selling Stockholders,&rdquo;
which we agreed to issue and sell an aggregate of 5,000,000 shares of common stock, consisting of 2,500,000 outstanding shares
of our common stock and 2,500,000 shares of our common stock issuable upon the exercise of the Warrants (the &ldquo;Private Placement&rdquo;).
The shares of common stock issued and the common stock issuable upon the exercise of the Warrants were issued pursuant to an exemption
from the registration requirements of the Securities Act provided in Section 4(a)(2) thereof and/or Rule 506 of Regulations D
promulgated thereunder. We received gross proceeds of $10,000,000 at the closing on January 21, 2021, before deducting fees owed
to the placement agent and other fees applicable to the offering. The aforementioned Securities Purchase Agreement contains customary
representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the
Company, other obligations of the parties and termination provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Each Warrant is exercisable
beginning July 21, 2021 at an exercise price of $6.03 per share, subject to adjustment as provided therein, and terminated five
and one-half years after the initial exercise date. The exercise price and number of the shares of our common stock issuable upon
exercising the Warrants will be subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization,
reorganization or similar transaction, as described therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="az_006"></A><B>SELLING STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The common stock being
offered by the Selling Stockholders are those previously issued to the Selling Stockholders, and those issuable to the Selling
Stockholders, upon exercise of the Warrants. For additional information regarding the issuances of those shares of common stock
and Warrants, see &ldquo;Private Placement of Shares of Common Stock and Warrants&rdquo; above. We are registering the shares
of common stock in order to permit the Selling Stockholders to offer the shares for resale from time to time. Except for the ownership
of the shares of common stock and the Warrants, the Selling Stockholders have not had any material relationship with us within
the past three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The table below lists
the Selling Stockholders and other information regarding the beneficial ownership of the shares of common stock by each of the
Selling Stockholders. The second column lists the number of shares of common stock beneficially owned by each Selling Stockholders
based on its ownership of the shares of common stock and Warrants, as of January 25, 2021, assuming exercise of the Warrants held
by the Selling Stockholders on that date, without regard to any limitations on exercises. The third column lists the shares of
common stock being offered by this prospectus by the Selling Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In accordance with
the terms of a registration rights agreement with the Selling Stockholders, this prospectus generally covers the resale of the
sum of (i) the number of shares of common stock issued to the selling shareholders in the &ldquo;Private Placement of Shares of
Common Stock and Warrants&rdquo; described above and (ii) the maximum number of shares of common stock issuable upon exercise
of the related Warrants, determined as if the outstanding Warrants were exercised in full as of the trading day immediately preceding
the date this registration statement was initially filed with the SEC, each as of the trading day immediately preceding the applicable
date of determination and all subject to adjustment as provided in the registration right agreement, without regard to any limitations
on the exercise of the Warrants. The fourth column assumes the sale of all of the shares offered by the Selling Stockholders pursuant
to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Under the terms of
the Warrants, a Selling Stockholder may not exercise the Warrants to the extent such exercise would cause such Selling Stockholder,
together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed
4.99% or 9.99%, as applicable, of our then outstanding common stock following such exercise, excluding for purposes of such determination
shares of common stock issuable upon exercise of the Warrants which have not been exercised. The number of shares in the second
column does not reflect this limitation. The Selling Stockholders may sell all, some or none of their shares in this offering.
See &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: left; font-size: 10pt; padding-left: 0.25pt">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number
                                         of shares<BR>
                                         of Common Stock<BR>
                                         Owned Prior to </B></FONT></TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Maximum
                                         Number <BR>
                                         of shares of<BR>
                                         Common Stock to<BR>
                                         be Sold Pursuant to </B></FONT></TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD><TD COLSPAN="5" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><B>Number of shares of<BR> Common Stock<BR> Owned After<BR> Offering(3)</B></TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left; font-size: 10pt; padding-left: 0.25pt"><B>Name
    of Selling Stockholder</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><B>Offering(1)(2)</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><B>this
                                         Prospectus</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percent</B></FONT></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; font-size: 10pt; padding-left: 0.25pt">3i, LP(4)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">250,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">500,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25pt">Armistice Capital Master Fund Ltd.(5)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0.25pt">Bigger Capital Fund, LP(6)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">250,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">500,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25pt">Boothbay Absolute Return Strategies LP(7)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">66,240</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">132,480</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25pt">Boothbay Diversified Alpha Master Fund, LP(8)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">33,760</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">67,520</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0.25pt">Cavalry Fund I LP(9)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">125,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">250,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25pt">Cavalry Special Ops Fund, LLC(10)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">125,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">250,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25pt">CVI Investments, Inc.(11)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">250,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">500,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25pt">Intracoastal Capital, LLC(12)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">375,480</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">750,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">480</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Kingsbrook Opportunities Master Fund
    LP(13)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">25,792</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">792</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Less than 1%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">This
                                         table and the information in the notes below are based upon information supplied by the
                                         Selling Stockholders and are based on shares of common stock outstanding as of January
                                         21, 2021. Beneficial ownership is determined in accordance with Rule 13d-3 under the
                                         Securities Act, and includes any shares as to which the Selling Stockholder has sole
                                         or shared voting power or investment power, and also any shares which the Selling Stockholder
                                         has the right to acquire within 60 days of the date hereof, whether through the exercise
                                         or conversion of any stock option, convertible security, warrant or other right. The
                                         indication herein that shares are beneficially owned is not an admission on the part
                                         of the Selling Stockholder that he, she or it is a direct or indirect beneficial owner
                                         of those shares.</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: left">All convertible
                                         securities of the Company held by the Selling Stockholders are subject to beneficial
                                         ownership limitations such that the shares of warrants may not be converted or exercised,
                                         respectively, if it would result in the holder exceeding the beneficial ownership limitation.
                                         The Warrants restrict the ability of the holder to exercise the warrants to the extent
                                         that the holder and its affiliates would beneficially own more than 4.99% of the common
                                         stock following such exercise, provided, however, that the holder has the ability to
                                         waive such ownership limitation upon 61 days prior notice and, provided, further, that
                                         in no event may the holder beneficially own more than 9.99% of the Company&rsquo;s common
                                         stock following such exercise.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: left">We do not know
                                         when or in what amounts a Selling Stockholder may offer shares for sale. The Selling
                                         Stockholders might not sell any or might sell all of the shares offered by this prospectus.
                                         Because the Selling Stockholders may offer all or some of the shares pursuant to this
                                         offering, and because there are currently no agreements, arrangements or understandings
                                         with respect to the sale of any of the shares, we cannot estimate the number of the shares
                                         that will be held by the Selling Stockholders after completion of the offering. However,
                                         for purposes of this table, we have assumed that, after completion of the offering, none
                                         of the shares covered by this prospectus will be held by the Selling Stockholders, including
                                         common stock issuable upon exercise of the Warrants issued in the Private Placement.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(4)</TD><TD STYLE="text-align: left">The shares reported
                                         under &ldquo;Number of shares of Common Stock Owned Prior to Offering&rdquo; consists
                                         of 250,000 shares of the common stock held by 3i, LP issued in the Private Placement
                                         of shares by the Company on January 21, 2021. In addition to the foregoing shares, as
                                         of January 25, 2021, 3i, LP held Warrants to purchase 250,000 shares of common stock
                                         that are not included in the shares reported under &ldquo;Number of shares of Common
                                         Stock Owned Prior to Offering&rdquo; because they are not exercisable until July 21,
                                         2021. The shares reported under &ldquo;Number of shares of Common Stock Being Offered&rdquo;
                                         consist of (i) the shares reported as beneficially owned by 3i, LP under &ldquo;Number
                                         of shares of Common Stock Owned Prior to Offering&rdquo; and (ii) the shares issuable
                                         upon exercise of the Warrants held by 3i, LP described above, in each case, without giving
                                         effect to the beneficial ownership limitation set forth in the Warrants. Maier J. Tarlow
                                         has sole voting and dispositive power with respect to the shares of common stock held
                                         by 3i, LP. The address of 3i, LP is 3i Fund, 140 Broadway 38 FL, New York, New York 10005.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(5)</TD><TD STYLE="text-align: left">The shares reported
                                         under &ldquo;Number of shares of Common Stock Owned Prior to Offering&rdquo; consists
                                         of 1,000,000 shares of the common stock held by Armistice Capital Master Fund Ltd. issued
                                         in the Private Placement of shares by the Company on January 21, 2021. In addition to
                                         the foregoing shares, as of January 25, 2021, Armistice Capital Master Fund Ltd. held
                                         Warrants to purchase 1,000,000 shares of common stock that are not included in the shares
                                         reported under &ldquo;Number of shares of Common Stock Owned Prior to Offering&rdquo;
                                         because they are not exercisable until July 21, 2021. The shares reported under &ldquo;Number
                                         of shares of Common Stock Being Offered&rdquo; consist of (i) the shares reported as
                                         beneficially owned by Armistice Capital Master Fund Ltd. under &ldquo;Number of shares
                                         of Common Stock Owned Prior to Offering&rdquo; and (ii) the shares issuable upon exercise
                                         of the Warrants held by Armistice Capital Master Fund Ltd. described above, in each case,
                                         without giving effect to the beneficial ownership limitation set forth in the Warrants.
                                         Steven Boyd has sole voting and dispositive power with respect to the shares of common
                                         stock held by Armistice Capital Master Fund Ltd. The address of Armistice Capital Master
                                         Fund Ltd. is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, New
                                         York 10022.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(6)</TD><TD STYLE="text-align: left">The shares reported
                                         under &ldquo;Number of shares of Common Stock Owned Prior to Offering&rdquo; consists
                                         of 250,000 shares of the common stock held by Bigger Capital Fund, LP issued in the Private
                                         Placement of shares by the Company on January 21, 2021. In addition to the foregoing
                                         shares, as of January 25, 2021, Bigger Capital Fund, LP held Warrants to purchase 250,000
                                         shares of common stock that are not included in the shares reported under &ldquo;Number
                                         of shares of Common Stock Owned Prior to Offering&rdquo; because they are not exercisable
                                         until July 21, 2021. The shares reported under &ldquo;Number of shares of Common Stock
                                         Being Offered&rdquo; consist of (i) the shares reported as beneficially owned by Bigger
                                         Capital Fund, LP under &ldquo;Number of shares of Common Stock Owned Prior to Offering&rdquo;
                                         and (ii) the shares issuable upon exercise of the Warrants held by Bigger Capital Fund,
                                         LP described above, in each case, without giving effect to the beneficial ownership limitation
                                         set forth in the Warrants. Michael Bigger has sole voting and dispositive power with
                                         respect to the shares of common stock held by Bigger Capital Fund, LP. The address of
                                         Bigger Capital Fund, LP is 11434 Glowing Sunset, Las Vegas, Nevada 89135.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(7)</TD><TD STYLE="text-align: left">The shares reported
                                         under &ldquo;Number of shares of Common Stock Owned Prior to Offering&rdquo; consists
                                         of 66,240 shares of the common stock held by Boothbay Absolute Return Strategies LP issued
                                         in the Private Placement of shares by the Company on January 21, 2021. In addition to
                                         the foregoing shares, as of January 25, 2021, Boothbay Absolute Return Strategies LP
                                         held Warrants to purchase 66,240 shares of common stock that are not included in the
                                         shares reported under &ldquo;Number of shares of Common Stock Owned Prior to Offering&rdquo;
                                         because they are not exercisable until July 21, 2021. The shares reported under &ldquo;Number
                                         of shares of Common Stock Being Offered&rdquo; consist of (i) the shares reported as
                                         beneficially owned by Boothbay Absolute Return Strategies LP under &ldquo;Number of shares
                                         of Common Stock Owned Prior to Offering&rdquo; and (ii) the shares issuable upon exercise
                                         of the Warrants held by Boothbay Absolute Return Strategies LP described above, in each
                                         case, without giving effect to the beneficial ownership limitation set forth in the Warrants.
                                         Boothbay Absolute Return Strategies LP, a Delaware limited partnership (the &ldquo;Fund&rdquo;),
                                         is managed by Boothbay Fund Management, LLC, a Delaware limited liability company (the
                                         &ldquo;Adviser&rdquo;). The Adviser, in its capacity as the investment manager of the
                                         Fund, has the power to vote and the power to direct the disposition of all securities
                                         held by the Fund. Ari Glass is the Managing Member of the Adviser. Each of the Fund,
                                         the Adviser and Mr. Glass disclaim beneficial ownership of these securities, except to
                                         the extent of any pecuniary interest therein. The address of Boothbay Absolute Return
                                         Strategies LP is c/o Kingsbrook Partners LP, 689 Fifth Avenue, 12th Floor, New York,
                                         New York 10022.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(8)</TD><TD STYLE="text-align: left">The shares reported
                                         under &ldquo;Number of shares of Common Stock Owned Prior to Offering&rdquo; consists
                                         of 33,760 shares of the common stock held by Boothbay Diversified Alpha Master Fund,
                                         LP issued in the Private Placement of shares by the Company on January 21, 2021. In addition
                                         to the foregoing shares, as of January 25, 2021, Boothbay Diversified Alpha Master Fund,
                                         LP held Warrants to purchase 33,760 shares of common stock that are not included in the
                                         shares reported under &ldquo;Number of shares of Common Stock Owned Prior to Offering&rdquo;
                                         because they are not exercisable until July 21, 2021. The shares reported under &ldquo;Number
                                         of shares of Common Stock Being Offered&rdquo; consist of (i) the shares reported as
                                         beneficially owned by Boothbay Diversified Alpha Master Fund, LP under &ldquo;Number
                                         of shares of Common Stock Owned Prior to Offering&rdquo; and (ii) the shares issuable
                                         upon exercise of the Warrants held by Boothbay Diversified Alpha Master Fund, LP described
                                         above, in each case, without giving effect to the beneficial ownership limitation set
                                         forth in the Warrants. Boothbay Diversified Alpha Master Fund, LP, a Cayman Islands limited
                                         partnership (the &ldquo;Fund&rdquo;), is managed by Boothbay Fund Management, LLC, a
                                         Delaware limited liability company (the &ldquo;Adviser&rdquo;). The Adviser, in its capacity
                                         as the investment manager of the Fund, has the power to vote and the power to direct
                                         the disposition of all securities held by the Fund. Ari Glass is the Managing Member
                                         of the Adviser. Each of the Fund, the Adviser and Mr. Glass disclaim beneficial ownership
                                         of these securities, except to the extent of any pecuniary interest therein. The address
                                         of Boothbay Diversified Alpha Master Fund, LP is c/o Kingsbrook Partners LP, 689 Fifth
                                         Avenue, 12th Floor, New York, New York 10022.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(9)</TD><TD STYLE="text-align: left">The shares reported
                                         under &ldquo;Number of shares of Common Stock Owned Prior to Offering&rdquo; consists
                                         of 125,000 shares of the common stock held by Cavalry Fund I LP issued in the Private
                                         Placement of shares by the Company on January 21, 2021. In addition to the foregoing
                                         shares, as of January 25, 2021, Cavalry Fund I LP held Warrants to purchase 125,000 shares
                                         of common stock that are not included in the shares reported under &ldquo;Number of shares
                                         of Common Stock Owned Prior to Offering&rdquo; because they are not exercisable until
                                         July 21, 2021. The shares reported under &ldquo;Number of shares of Common Stock Being
                                         Offered&rdquo; consist of (i) the shares reported as beneficially owned by Cavalry Fund
                                         I LP under &ldquo;Number of shares of Common Stock Owned Prior to Offering&rdquo; and
                                         (ii) the shares issuable upon exercise of the Warrants held by Cavalry Fund I LP described
                                         above, in each case, without giving effect to the beneficial ownership limitation set
                                         forth in the Warrants. Thomas Walsh has sole voting and dispositive power with respect
                                         to the shares of common stock held by Cavalry Fund I LP. The address of Cavalry Fund
                                         I LP is 82 E. Allendale Road, Suite 5B, Saddle River, New Jersey 07458.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(10)</TD><TD STYLE="text-align: left">The shares reported
                                         under &ldquo;Number of shares of Common Stock Owned Prior to Offering&rdquo; consists
                                         of 125,000 shares of the common stock held by Cavalry Special Ops Fund, LLC issued in
                                         the Private Placement of shares by the Company on January 21, 2021. In addition to the
                                         foregoing shares, as of January 25, 2021, Cavalry Special Ops Fund, LLC held Warrants
                                         to purchase 125,000 shares of common stock that are not included in the shares reported
                                         under &ldquo;Number of shares of Common Stock Owned Prior to Offering&rdquo; because
                                         they are not exercisable until July 21, 2021. The shares reported under &ldquo;Number
                                         of shares of Common Stock Being Offered&rdquo; consist of (i) the shares reported as
                                         beneficially owned by Cavalry Special Ops Fund, LLC under &ldquo;Number of shares of
                                         Common Stock Owned Prior to Offering&rdquo; and (ii) the shares issuable upon exercise
                                         of the Warrants held by Cavalry Special Ops Fund, LLC described above, in each case,
                                         without giving effect to the beneficial ownership limitation set forth in the Warrants.
                                         Thomas Walsh has sole voting and dispositive power with respect to the shares of common
                                         stock held by Cavalry Special Ops Fund, LLC. The address of Cavalry Special Ops Fund,
                                         LLC is 82 E. Allendale Road, Suite 5B, Saddle River, New Jersey 07458.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(11)</TD><TD STYLE="text-align: left">The shares reported
                                         under &ldquo;Number of shares of Common Stock Owned Prior to Offering&rdquo; consists
                                         of 250,000 shares of the common stock held by CVI Investments, Inc. issued in the Private
                                         Placement of shares by the Company on January 21, 2021. In addition to the foregoing
                                         shares, as of January 25, 2021, CVI Investments, Inc. held Warrants to purchase 250,000
                                         shares of common stock that are not included in the shares reported under &ldquo;Number
                                         of shares of Common Stock Owned Prior to Offering&rdquo; because they are not exercisable
                                         until July 21, 2021. The shares reported under &ldquo;Number of shares of Common Stock
                                         Being Offered&rdquo; consist of (i) the shares reported as beneficially owned by CVI
                                         Investments, Inc. under &ldquo;Number of shares of Common Stock Owned Prior to Offering&rdquo;
                                         and (ii) the shares issuable upon exercise of the Warrants held by CVI Investments, Inc.
                                         described above, in each case, without giving effect to the beneficial ownership limitation
                                         set forth in the Warrants. Heights Capital Management, Inc., the authorized agent of
                                         CVI Investments, Inc (&ldquo;CVI&rdquo;), has discretionary authority to vote and dipose
                                         of the shares held by CVI and may be deemed to be the beneficial owner of these shares.
                                         Martin Kobinger, in his capacity as Investment Manager of Heights Capital Management,
                                         Inc., may also be deemed to have investment discretion and voting power over the shares
                                         held by CVI. Mr. Kobinger disclaims any such beneficial ownership of the shares. CVI
                                         Investments, Inc.is affiliated with one or more FINRA member, none of whom are currently
                                         expected to participate in this offering. The address of CVI Investments, Inc. is c/o
                                         Heights Capital Management, 101 California Street, Suite 3250, San Francisco, California
                                         94111.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(12)</TD><TD STYLE="text-align: left">The shares reported
                                         under &ldquo;Number of shares of Common Stock Owned Prior to Offering&rdquo; consists
                                         of (i) 375,000 shares of the common stock held by Intracoastal Capital, LLC issued in
                                         the Private Placement of shares by the Company on January 21, 2021 and (i) 480 shares
                                         of common stock underlying warrants exercisable within 60 days of January 25, 2021 held
                                         by Intracoastal Capital, LLC. In addition to the foregoing shares, as of January 25,
                                         2021, Intracoastal Capital, LLC held Warrants to purchase 375,000 shares of common stock
                                         that are not included in the shares reported under &ldquo;Number of shares of Common
                                         Stock Owned Prior to Offering&rdquo; because they are not exercisable until July 21,
                                         2021. The shares reported under &ldquo;Number of shares of Common Stock Being Offered&rdquo;
                                         consist of (i) the shares reported as beneficially owned by Intracoastal Capital, LLC
                                         under &ldquo;Number of shares of Common Stock Owned Prior to Offering&rdquo; and (ii)
                                         the shares issuable upon exercise of the Warrants held by Intracoastal Capital, LLC described
                                         above, in each case, without giving effect to the beneficial ownership limitation set
                                         forth in the Warrants. Mitchell P. Kopin (&ldquo;Mr. Kopin&rdquo;) and Daniel B. Asher
                                         (&ldquo;Mr. Asher&rdquo;), each of whom are managers of Intracoastal Capital LLC (&ldquo;Intracoastal&rdquo;),
                                         have shared voting control and investment discretion over the securities reported herein
                                         that are held by Intracoastal. As a result, each of Mr. Kopin and Mr. Asher may be deemed
                                         to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange
                                         Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;)) of the securities reported
                                         herein that are held by Intracoastal. The address of Intracoastal Capital, LLC is 2211A
                                         Lakeside Drive, Bannockburn, Illinois 60015.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(13)</TD><TD STYLE="text-align: left">The shares reported
                                         under &ldquo;Number of shares of Common Stock Owned Prior to Offering&rdquo; consists
                                         of (i) 25,000 shares of the common stock held by Kingsbrook Opportunities Master Fund
                                         LP issued in the Private Placement of shares by the Company on January 21, 2021 and (i)
                                         792 shares of common stock underlying warrants exercisable within 60 days of January
                                         25, 2021 held by Kingsbrook Opportunities Master Fund LP. In addition to the foregoing
                                         shares, as of January 25, 2021, Kingsbrook Opportunities Master Fund LP held Warrants
                                         to purchase 25,000 shares of common stock that are not included in the shares reported
                                         under &ldquo;Number of shares of Common Stock Owned Prior to Offering&rdquo; because
                                         they are not exercisable until July 21, 2021. The shares reported under &ldquo;Number
                                         of shares of Common Stock Being Offered&rdquo; consist of (i) the shares reported as
                                         beneficially owned by Kingsbrook Opportunities Master Fund LP under &ldquo;Number of
                                         shares of Common Stock Owned Prior to Offering&rdquo; and (ii) the shares issuable upon
                                         exercise of the Warrants held by Kingsbrook Opportunities Master Fund LP described above,
                                         in each case, without giving effect to the beneficial ownership limitation set forth
                                         in the Warrants. Kingsbrook Partners LP (&ldquo;Kingsbrook Partners&rdquo;) is the investment
                                         manager of Kingsbrook Opportunities Master Fund LP (&ldquo;Kingsbrook Opportunities&rdquo;)
                                         and consequently has voting control and investment discretion over securities held by
                                         Kingsbrook Opportunities. Kingsbrook Opportunities GP LLC (&ldquo;Opportunities GP&rdquo;)
                                         is the general partner of Kingsbrook Opportunities and may be considered the beneficial
                                         owner of any securities deemed to be beneficially owned by Kingsbrook Opportunities.
                                         KB GP LLC (&ldquo;GP LLC&rdquo;) is the general partner of Kingsbrook Partners and may
                                         be considered the beneficial owner of any securities deemed to be beneficially owned
                                         by Kingsbrook Partners. Ari J. Storch, Adam J. Chill and Scott M. Wallace are the sole
                                         managing members of Opportunities GP and GP LLC and as a result may be considered beneficial
                                         owners of any securities deemed beneficially owned by Opportunities GP and GP LLC. Each
                                         of Kingsbrook Partners, Opportunities GP, GP LLC and Messrs. Storch, Chill and Wallace
                                         disclaim beneficial ownership of these securities. The address of Kingsbrook Opportunities
                                         Master Fund LP is c/o Kingsbrook Partners LP, 689 Fifth Avenue, 12th Floor, New York,
                                         New York 10022.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><B>Relationship with the Selling Stockholders</B> &nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition to the
Securities Purchase Agreement, on January 18, 2021, in connection with the Private Placement, we entered into a registration rights
agreement with the Selling Stockholders, or the Registration Rights Agreement. Also on January 21, 2021, we entered into the Warrants
with the Selling Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><I>Registration Rights
Agreement</I> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to the Registration
Rights Agreement with each of the selling stockholders, we agreed to prepare and file with the SEC a registration statement that
permits the resale of the selling stockholders&rsquo; shares and, subject to certain exceptions, use reasonable best efforts to
keep the registration statement of which this prospectus forms a part effective under the Securities Act until the earlier of
until the date that all registrable securities covered by the registration statement of which this prospectus forms a part: (i)
have been sold, thereunder or pursuant to Rule 144, or (ii) may be sold without volume or manner-of-sale restrictions pursuant
to Rule 144 and without the requirement for the Company to be in compliance with the current public information requirement under
Rule 144, as determined by the counsel to the Company pursuant to a written opinion letter to such effect, addressed and acceptable
to the Company&rsquo;s transfer agent and the affected Selling Stockholder. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have also agreed,
among other things, to indemnify the Selling Stockholders and their officers, directors, members, employees and agents, successors
and assigns under the registration statement from certain liabilities and to pay all fees and expenses (excluding any legal fees
of the selling holder(s), and any underwriting discounts and selling commissions) incident to our obligations under the Registration
Rights Agreement. &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><I>Warrants</I> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Warrants are exercisable
at any time on or after July 21, 2021 and entitle the Selling Stockholders to purchase shares of our common stock until July 21,
2026 at a price per share equal to $6.03 per share, subject to certain adjustments.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="az_007"></A><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Each Selling Stockholder
of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their
securities covered hereby on Nasdaq or any other stock exchange, market or trading facility on which the securities are traded
or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of
the following methods when selling securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">ordinary
                                         brokerage transactions and transactions in which the broker-dealer solicits purchasers;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">block
                                         trades in which the broker-dealer will attempt to sell the securities as agent but may
                                         position and resell a portion of the block as principal to facilitate the transaction;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">purchases
                                         by a broker-dealer as principal and resale by the broker-dealer for its account;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">an
                                         exchange distribution in accordance with the rules of the applicable exchange;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">privately
                                         negotiated transactions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">settlement
                                         of short sales;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">in
                                         transactions through broker-dealers that agree with the Selling Stockholders to sell
                                         a specified number of such securities at a stipulated price per security;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">through
                                         the writing or settlement of options or other hedging transactions, whether through an
                                         options exchange or otherwise;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a
                                         combination of any such methods of sale; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">any
                                         other method permitted pursuant to applicable law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Selling Stockholders
may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather
than under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Broker-dealers engaged
by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction
not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction
a markup or markdown in compliance with FINRA IM-2440.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In connection with
the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions
they assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions,
or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter
into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities
which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which
securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended
to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Selling Stockholders
and any broker-dealers or agents that are involved in selling the securities may be deemed to be &ldquo;underwriters&rdquo; within
the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement
or understanding, directly or indirectly, with any person to distribute the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company is required
to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed
to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the
Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We agreed to keep
this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders
without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement
for the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule
of similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act
or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers
if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not
be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or
qualification requirement is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Under applicable rules
and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously
engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation
M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions
of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases
and sales of the common stock by the Selling Stockholders or any other person. We will make copies of this prospectus available
to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior
to the time of the sale (including by compliance with Rule 172 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="az_008"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Honigman LLP, Kalamazoo, Michigan, will
issue a legal opinion as to the validity of the securities offered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B><A NAME="az_009"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0">The consolidated financial statements as of December 31, 2019
and 2018 and for each of the two years in the period ended December 31, 2019 incorporated by reference in this Prospectus and in
the Registration Statement have been so incorporated in reliance on the report of BDO USA, LLP, an independent registered public
accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. The
report on the consolidated financial statements contains an explanatory paragraph regarding the Company's ability to continue as
a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B><A NAME="az_010"></A>WHERE YOU CAN FIND
MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We file annual, quarterly
and current reports, proxy statements and other information with the SEC. You can access the electronic versions of these filings,
free of charge, on the SEC&rsquo;s internet website found at <U>http://www.sec.gov</U>. These filings will be available as soon
as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The information found on,
or that may be accessed through, our website is not incorporated by reference in this prospectus and should not be considered
a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
prospectus omits some information contained in the registration statement in accordance with SEC rules and regulations. You should
review the information and exhibits included in the registration statement for further information about us and the securities
offered by us. Statements in this prospectus concerning any document filed as an exhibit to the registration statement or otherwise
filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the
complete document to evaluate these statements</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B><A NAME="az_011"></A>INCORPORATION OF CERTAIN
DOCUMENTS BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The SEC&rsquo;s rules
allow us to &ldquo;incorporate by reference&rdquo; information into this prospectus, which means that we can disclose important
information to you by referring you to another document filed separately with the SEC. The information incorporated by reference
is deemed to be part of this prospectus, and later information that we file with the SEC will automatically update and supersede
that information. Any statement contained in a previously filed document incorporated by reference shall be deemed to be modified
or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus modifies or replaces
that statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We incorporate by
reference the documents listed below and any future filings made by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of
the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) between the date of this prospectus and the termination
of the offering of the securities described in this prospectus. We are not, however, incorporating by reference any documents
or portions thereof, whether specifically listed below or filed in the future, that are not deemed &ldquo;filed&rdquo; with the
SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000155837020003385/nrbo-20191231x10k.htm" STYLE="-sec-extract: exhibit">Our Annual Report on Form 10-K for the year ended December 31, 2019,</A> filed with the SEC on
                                         March 30, 2020;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the
                                         information specifically incorporated by reference into our <A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000155837020003385/nrbo-20191231x10k.htm" STYLE="-sec-extract: exhibit">Annual Report on Form 10-K for the fiscal year ended December 31, 2019</A> from our <A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000104746920002703/a2241501zdef14a.htm" STYLE="-sec-extract: exhibit">definitive proxy statement on Schedule 14A (other than information furnished rather than filed) filed with the SEC on April 29, 2020;</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Our
                                         Quarterly Reports on Form 10-Q for the quarters ended <A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000155837020006879/nrbo-20200331x10q.htm" STYLE="-sec-extract: exhibit">March 31, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000155837020010309/nrbo-20200630x10q.htm" STYLE="-sec-extract: exhibit">June 30, 2020</A> and
                                         <A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000155837020013826/nrbo-20200930x10q.htm" STYLE="-sec-extract: exhibit">September 30, 2020</A>, filed with the SEC on May 20, 2020, August 11, 2020 and November
                                         13, 2020, respectively;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Our
                                         Current Reports on Form 8-K or Form 8-K/A (other than information furnished rather than
                                         filed) filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000110465920001824/a20-1384_18ka.htm" STYLE="-sec-extract: exhibit">January 7, 2020</A>,&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000155837020000207/nrbo-20191230x8ka.htm" STYLE="-sec-extract: exhibit">January 22, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000155837020000476/f8-k.htm">February 4, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000155837020000773/f8-k.htm" STYLE="-sec-extract: exhibit">February 13, 2020,</A> <A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000155837020001074/f8-ka.htm" STYLE="-sec-extract: exhibit">February 20, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000155837020003927/nrbo-20200413x8k.htm" STYLE="-sec-extract: exhibit">April 15, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000155837020006943/tmb-20200526x8k.htm" STYLE="-sec-extract: exhibit">May 26, 2020</A>,<A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000155837020007610/tmb-20200618x8k.htm" STYLE="-sec-extract: exhibit"> June 18, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000155837020010954/tmb-20200830x8k.htm" STYLE="-sec-extract: exhibit">September 2, 2020,</A>&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000155837021000051/tmb-20201231x8k.htm" STYLE="-sec-extract: exhibit">January 6, 2021</A>,<A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000155837021000181/tmb-20210109x8k.htm" STYLE="-sec-extract: exhibit"> January 13, 2021</A>, and <A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000155837021000329/tmb-20210118x8k.htm" STYLE="-sec-extract: exhibit">January 21, 2021</A>, respectively;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">The
                                         description of our common stock contained in our<A HREF="https://www.sec.gov/Archives/edgar/data/1638287/000110465916128353/a15-18801_108a12b.htm" STYLE="-sec-extract: exhibit"> registration statement on Form 8-A (File No. 00137809)</A> filed with the SEC on June 20, 2016, pursuant to Section 12(b) of the Exchange
                                         Act, including any amendments or reports filed for the purpose of updating such descriptions;
                                         and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Any
                                         other filings we make pursuant to the Exchange Act after the date of filing the registration
                                         statement of which this prospectus is a part and prior to effectiveness of the registration
                                         statement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">These documents may also
be accessed on our website at <I>www.neurobopharma.com</I>. Information contained in, or accessible through, our website is not
a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We will provide without charge to each person, including any beneficial owners, to whom this prospectus
is delivered, upon his or her written or oral request, a copy of any or all reports or documents referred to above which have been or
may be incorporated by reference into this prospectus but not delivered with this prospectus, excluding exhibits to those reports or documents
unless they are specifically incorporated by reference into those documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">You may request a
free copy of any of the documents incorporated by reference in this prospectus by writing or telephoning us at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">NeuroBo
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">200 Berkeley
Street</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">Office
19th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">Boston,
Massachusetts 02116</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">Attention:
Corporate Secretary</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(857) 702-9600</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 48.95pt">Exhibits to the
filings will not be sent, however, unless those exhibits have specifically been incorporated by reference into this prospectus
and any accompanying prospectus. In order to ensure timely delivery of the documents incorporated by reference in this prospectus,
any request should be made no later than five business days prior to the date on which you plan to make a final investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="border-bottom: Black medium double; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5,000,000 Shares </B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm213982d3_424b3img01.jpg" ALT=""></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS </B></P>



<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>January 29, 2021</B></P>





<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="border-bottom: Black medium double; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 18; Options: NewSection Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm213982d3_424b3img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm213982d3_424b3img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% /$# 2(  A$! Q$!_\0
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M^TX.ULX-9J[*=EH2T<YI,Y--EE2!"\KJB#JS' %,>Q)13%=74,I!!Y!'>G4
M+1110 4444 %%%% !1110 4F>:6H)[F&W&Z61$!Z%FQ0)M+<FS0*I_VG8_\
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M$#TWL!6*=431_!45])\WE6JL!ZG;P*Q-"\+)K-LNK>(2]W<W/SB)F(2-3T
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M0OMD16++GU!]*7+9#YO>L;=%%%(L**** $(!ZT8&,444 &!Z48%%% "T444
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<",@8Z5);VD%I'LMXEC7KA:**+A9$U%%% S__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
